Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure clue found in coronary sinus blood

NCT ID NCT07436377

Knowledge-focused Sponsor: Trakya University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at blood gas levels taken from a vein near the heart during a pacemaker-like procedure called CRT. The goal is to see if these measurements can help predict which heart failure patients will respond well to the therapy. Researchers are following 65 patients to track outcomes like hospitalizations and heart function changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which heart failure patients are most likely to benefit from cardiac resynchronization therapy (CRT) before the procedure.
What could go wrong
This is a small, observational study with only 65 participants. It aims to find patterns, not test a treatment, so it may not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

65 people

The number who actually took part.

Started

Sep 2022

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Heart failure patients with an ejection fraction below 35, NYHA physical capacity of 2-3, and QRS duration longer than 135 ms on ECG, whose symptoms persist despite optimal medical treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients diagnosed with heart failure, with an EF \<35, and in heart failure stages 2-3-4 despite optimal medical therapy. 2. Those who agree to participate in the study. 3. Patients aged 18 years and older. 4. Patients with a QRS duration of 135 ms or more on ECG. Exclusion Criteria: 1. Patients with EF 35 or higher. 2. QRS duration on ECG less than 130 milliseconds. 3. Not receiving the maximum tolerable dose of medication for KY. 4. Absence of left bundle branch block morphology on ECG. 5. History of acute myocardial infarction within the last 3 months. 6. Estimated life expectancy of less than 1 year. 7. History of cardiac surgery within the last 3 months. 8. Elective cardiac surgery planned. 9. Patients scheduled for CRT prior to nodal ablation. 10. Patients with intracardiac shunts. 11. Those who refuse to participate in the study. 12. Chronic lung diseases (COPD, emphysema, bronchitis, etc.). -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac resynchronization therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac resynchronization therapy Coronary sinus Heart failure

Contacts and locations

Locations

  • Trakya University Faculty of Medicine Hospital

    Edirne, 22100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.